G1, Revolution lead $116m in new VC funding

Count G1 Therapeutics and Revolution Medicines among the biotechnology companies benefitting from a 2014 boom in venture capital funding that has spilled over into 2015.

Count G1 Therapeutics and Revolution Medicines among the biotechnology companies benefitting from a 2014 boom in venture capital funding that has spilled over into 2015.

Cancer-focused G1 in Research Triangle Park, North Carolina raised a $33m Series B VC funding round to advance its Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category